subscribe
Quick Links
RESOURCES
Get in Touch
Copyright © All Rights Reserved by Hetero Healthcare Limited
We aim to improve the quality life of the people with our product line and along with a continuous Research and Development process. To be Recognized as an Innovative Pharmaceutical Company satisfying needs of the Customers, Doctors and Chemists.
Launched first generic 'COVIFOR' (Remdesivir) in India for the treatment of COVID-19 (licensing agreement with Gilead Sciences Inc.)
Basic manufacturer of Oseltamivir (sub-licensing agreement with Hoffman-La Rosche, Switzerland).
Launched first generic Bictegravir combination therapy in India under the brand name 'TAFFIC'.
Launched 'TAFERO-EM', first generic fixed-dose combination of 'Emtricitabine and Tenofovir Alafenamide' in India.
Launched biosimilar Rituximab for the treatment of chronic leukaemia.
Won "Express Pharma Excellence Award for COVID-19 drug launch" rewarding our contribution to provide COVIFOR(Remdesivir) access to more than 1 lakh patients.
Won "Certificate of Excellence" Gold Award for ITBOR from AWACS under new introductions of "ACUTE" category amongst the top 21-50 companies for 2019.
Copyright © All Rights Reserved by Hetero Healthcare Limited
